Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Annexon Biosciences (Nasdaq: ANNX), a biopharmaceutical company advancing late-stage clinical therapies for neuroinflammatory diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
Douglas Love, President and CEO, will present on Tuesday, January 14, 2025, at 3:00 p.m. PST. The presentation will be available via a live webcast under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay will be accessible on the website for 30 days post-event.
Positive
- None.
Negative
- None.
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PST.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is harnessing classical complement-driven neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
When will Annexon Biosciences present at the J.P. Morgan Healthcare Conference?
Who will be presenting for Annexon Biosciences at the J.P. Morgan Healthcare Conference?
How can I watch the Annexon Biosciences presentation at the J.P. Morgan Healthcare Conference?
How long will the replay of the Annexon Biosciences presentation be available?
What is the focus of Annexon Biosciences' clinical platform?
What is the stock symbol for Annexon Biosciences?
